Skip to main content

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate Enrollment and follow-up continue in 1L patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic...

Continue reading

Copper Quest Closes $1,927,000 Private Placement

// Not for distribution to the United States newswire services or for dissemination in the United States // VANCOUVER, British Columbia, Dec. 05, 2025 (GLOBE NEWSWIRE) — Copper Quest Exploration Inc. (CSE: CQX; FRA: 3MX) (“Copper Quest” or the “Company”) is pleased to announce that, further to its news release dated December 1, 2025, it has issued an aggregate of 10,142,104 flow-through shares of the Company (the “FT Shares“, and each, a “FT Share“) at a price of $0.19 per FT Share for aggregate gross proceeds of $1,927,000 in connection with its previously announced fully subscribed non-brokered private placement (the “Private Placement“). Each FT Share constitutes a “flow-through share” within the meaning of the Income Tax Act (Canada) (the “Tax Act“) and the gross proceeds of the...

Continue reading

Webus International Limited Issues Clarification on Previous Announcement Related to Expedia Group

New York, USA, Dec. 05, 2025 (GLOBE NEWSWIRE) — Webus International Limited (“Webus” or the “Company”) provides the following clarification regarding a press release on October 21, 2025, titled “Webus International Limited to Expand Wetour’s Expedia TAAP Partnership with Integration of Expedia Group’s Newly Announced AI Trip Planner and APIs.” (the “Press Release”): The Press Release contains inaccurate descriptions of the scope of Webus’ relationship with Expedia Group, which Webus now seeks to clarify as follows:Webus’ previous engagement with Expedia Group was limited exclusively to its participation in the Expedia Travel Agent Affiliate Program (TAAP).Webus has never had access to Expedia Group’s Smart Trip AI™, B2B APIs, or any other proprietary AI technologies or trademarks nor were Webus...

Continue reading

Sable Announces Adoption of New Equity Incentive Plan

VANCOUVER, British Columbia, Dec. 05, 2025 (GLOBE NEWSWIRE) — Sable Resources Ltd. (“Sable” or the “Company”) (TSXV: SAE | OTCQB: SBLRF) is pleased to announce that the shareholders of the Company provided near unanimous approval of a new omnibus equity incentive plan (the “Equity Incentive Plan”) at the Company’s annual general and special meeting of shareholders held earlier today (the “Meeting”). All other matters advanced at the Meeting, including setting the board at five members, re-election of directors and appointment of BDO Canada LLP as auditor, were also approved near unanimously. The Company adopted the Equity Incentive Plan to provide more flexibility than that provided under the previous stock option plan and restricted share unit plan of the Company (collectively, the “Legacy Plans”). The Equity Incentive Plan provides...

Continue reading

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Vancouver, Canada, Dec. 05, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced today that on December 4, 2025, the Company received a written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company’s closing bid price for its common shares was below $1.00 per share for the last 30 consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until June 2, 2026, to regain compliance with the minimum bid price requirement....

Continue reading

Rocket Doctor Announces Granting of RSUs and Options and a Change of CFO

Vancouver, BC, Dec. 05, 2025 (GLOBE NEWSWIRE) — Rocket Doctor AI Inc.’s (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) announces that Christopher Cherry shall assume the role of Interim Chief Financial Officer, to replace David Worner, effective December 8, 2025. Mr. Cherry is currently the Company’s Chair of the Audit Committee. The Company thanks Mr. Worner for his services to the Company and wishes him all the best in future endeavours. Additionally, the Company has granted an aggregate 579,028 stock options, exercisable at $0.84 per share and valid for a term of three or five years, and an aggregate 931,112 restricted share units, valid for a term between two to five years, to executive officers, directors and consultants of the Company and its subsidiary, Rocket Doctor Inc. The stock options and restricted...

Continue reading

Fly-E Group, Inc. Announces Receipt of Delinquency Notice from Nasdaq Regarding Delayed Form 10-Q

NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) — Fly-E Group, Inc. (NASDAQ: FLYE, the “Company”), an electric vehicle company engaged in designing, installing, selling and renting smart electric motorcycles, electric bikes, and electric scooters, announced today that on November 25, the Company received a written notice (the “Notice”) from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it currently does not satisfy Listing Rule 5250(c)(1), as a result of not having timely filed with the U.S. Securities and Exchange Commission (the “Commission”) its Form 10-Q for the period ended September 30, 2025 (the “Form 10-Q”). The Notice is a notification of deficiency, not of imminent delisting, and has no immediate effect on the listing or trading of the Company’s securities...

Continue reading

Skyharbour Closes $2.1 Million Private Placement of Flow-Through Shares

Vancouver, BC, Dec. 05, 2025 (GLOBE NEWSWIRE) — Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) (the “Company”) is pleased to announce that it has closed a non-brokered private placement (the “Private Placement”) financing for total gross proceeds of CAD $2,103,898.94. The Private Placement was mostly subscribed for by several strategic institutional investors. The funds will be applied towards the Company’s upcoming 2026 exploration campaign including exploration and drilling at its co-flagship Russell (“RL”) and Moore Lake Uranium Projects. The Company has allotted and issued 5,069,636 flow-through shares (the “FT Shares”) at a price of CAD $0.415 per FT Share. The FT Shares as defined in subsection 66(15) of the Income Tax Act (Canada) (“ITA”) as presently constituted, shall qualify for the federal 30%...

Continue reading

Colabor Group Announces Resignation of Director

SAINT-BRUNO-DE-MONTARVILLE, Quebec, Dec. 05, 2025 (GLOBE NEWSWIRE) — Colabor Group Inc. (TSX: GCL) (“Colabor” or the “Company”) announces that Ms. Danièle Bergeron has tendered her resignation as director of the Company, which resignation follows her acceptance of a position with a major company. “On behalf of the Board of Directors, I would like to extend our sincere appreciation to Ms. Bergeron for her valuable contribution, expertise and meaningful impact she has made to the Board and the Company throughout her tenure,” said Mr. Denis Mathieu, Interim Chairman of the Board of Directors of the Company. About Colabor Colabor is a distributor and wholesaler of food and related products serving the hotel, restaurant and institutional markets or “HRI” in Quebec and in the Atlantic provinces, as well as the retail market....

Continue reading

Parsons Selected As Lead Designer For $441 Million I-70 Rocheport To Columbia Design-Build Project

CHANTILLY, Va., Dec. 05, 2025 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that the Missouri Highways and Transportation Commission has selected the Emery Sapp & Sons (ESS)-Parsons Team to deliver the Interstate 70 Rocheport to Columbia Design-Build project. The $441 million reconstruction effort will improve a vital segment of I-70 through Boone County, adding a third lane of travel in each direction, modernizing pavement and bridges, and enhancing interchange operations to support safer and more efficient freight and passenger movement. Construction is expected to begin in mid-2026 and be completed by December 2029. “As Missouri looks to strengthen one of its most important transportation corridors, we are proud to bring our design-build expertise and local presence to this transformative project,”...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.